Sankyo Benicar HCT approved
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sankyo's Benicar HCT (olmesartan/hydrochlorothiazide) will be available in second half 2003. FDA cleared the combination of Sankyo's angiotensin II receptor blocker Benicar and HCTZ June 5 for second-line treatment of hypertension. FDA's Benicar review suggested that the ARB is similar to other agents in the class (1Pharmaceutical Approvals Monthly Sept. 1, 2002, p. 35). Benicar HCT will be available in three fixed-dose combinations: 20 mg olmesartan/12.5 mg HCTZ, 40 mg/12.5 mg and 40 mg/25 m
You may also be interested in...
Sankyo Benicar Offers No Significant Advantage Over Other ARBs, FDA Says
Sankyo’s antihypertensive Benicar (olmesartan medoxomil) may not offer significant benefits over the other six approved angiotensin II receptor blockers, FDA said in review documents for the NDA.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.